Alteronol Enhances the Anti-tumor Activity and Reduces the Toxicity of High-Dose Adriamycin in Breast Cancer

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Adriamycin (ADM) is a primary breast cancer chemotherapy drug.
• Acquired drug resistance and normal tissue toxicity are significant clinical challenges with ADM.
• Alteronol exhibits known anti-tumor properties.

Purpose of the Study:

• To investigate the synergistic anti-tumor effects of combining alteronol with ADM in breast cancer.
• To elucidate the underlying molecular mechanisms of this drug combination.
• To evaluate the efficacy and toxicity of the combination in preclinical models.

Main Methods:

• In vitro studies using breast cancer 4T1 cells to assess cell cycle progression, protein expression, and apoptosis.
• In vivo studies in tumor-bearing mice to evaluate tumor growth inhibition and organ toxicity.
• Analysis of cell cycle regulators (CDC2, Cyclin B1), kinase activation (p38, JNK), reactive oxygen species (ROS) levels, mitochondrial function, and apoptosis markers (PARP, Bax, caspase-3/9, Bcl-2).

Main Results:

• The combination of alteronol and ADM significantly inhibited breast cancer cell proliferation by inducing G2/M phase cell cycle arrest.
• Co-treatment activated p38 and JNK kinases, increased ROS levels, triggered mitochondrial dysfunction, and promoted apoptosis via cytochrome c release and modulation of apoptosis-related proteins.
• In vivo, a low-dose combination (alteronol 2 mg/kg + ADM 1 mg/kg) achieved tumor inhibition comparable to high-dose ADM (8 mg/kg) with reduced toxicity to major organs.

Conclusions:

• The combination of alteronol and ADM demonstrates synergistic anti-tumor activity in breast cancer.
• This combination effectively inhibits tumor growth and induces apoptosis through multiple molecular pathways.
• Low-dose alteronol and ADM offer a promising strategy to enhance breast cancer treatment efficacy while minimizing systemic toxicity.